Condition: Aplastic Anemia · TPO Receptor Agonists · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
This prospective, single center, single-arm study aims to evaluate the efficacy and safety of anti-human T lymphocyte porcine immunoglobulin (p-ALG) in combination with cyclosporine and Romiplostim in treating severe aplastic anemia (SAA). It will include 48 patients with newly diagnosed SAA.
This description comes directly from the study's public registry record.
Lele Zhang, PhD · 15811139278 · zhanglele@ihcams.ac.cn
Meili Ge, PhD
Always discuss trial participation with your own doctor first.
| Regenerative Medicine Center and Red Blood Cell Disorders Center | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06613880